Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT Study

August 12, 2026 updated by: Thomas Jefferson University

Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology ENGAGEMENT Study (Virtual Genetics Board)

This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

PRIMARY OBJECTIVE:

I. To assess perceived usefulness of a virtual genetics board.

SECONDARY OBJECTIVE:

I. To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge.

OUTLINE:

Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

Study Type

Observational

Enrollment (Actual)

118

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Non-genetic providers who perform prostate cancer (PCA) genetic testing for men in their practices (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers)

Description

Inclusion Criteria:

Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study:

  • Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer.
  • Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers)
  • Scientists and researchers
  • Advocacy or patient stakeholder organization members

Exclusion Criteria:

• Non-medical providers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Observational (survey, virtual genetic board, interview)
Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.
Other: Survey Administration
Complete survey
Other: Interview
Complete interview
Other: Educational Intervention
Attend virtual genetics board
Other Names:
  • Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mean Likert scaled perceived usefulness scores of the virtual genetics board
Time Frame: After virtual genetics board
Perceived usefulness will be judged against a benchmark mean score of 5/7.
After virtual genetics board

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Means or changes in means of Likert scaled acceptability/feasibility
Time Frame: Before and after virtual genetics board
Will be summarized by means, standard deviations, and 95% confidence intervals.
Before and after virtual genetics board
Perceived ease of use
Time Frame: After virtual genetics board
Will be summarized by means, standard deviations, and 95% confidence intervals.
After virtual genetics board
Self-efficacy for recommendations
Time Frame: Before and after virtual genetics board
Will be summarized by means, standard deviations, and 95% confidence intervals.
Before and after virtual genetics board
Change in mean scores on 17 genetics knowledge test questions
Time Frame: Baseline up to post-virtual genetics board
Will be summarized by means, standard deviations, and 95% confidence intervals.
Baseline up to post-virtual genetics board

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thomas Jefferson University

Investigators

  • Principal Investigator: Amy Leader, DrPH, MPH, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 21, 2020

Primary Completion (Actual)

June 2, 2022

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

February 19, 2021

First Submitted That Met QC Criteria

March 4, 2021

First Posted (Actual)

March 9, 2021

Study Record Updates

Last Update Posted (Actual)

August 14, 2026

Last Update Submitted That Met QC Criteria

August 12, 2026

Last Verified

August 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 20F.936
  • JT 16041 (Other Identifier: JeffTrial Number)
  • 080-27000-X17501 (Other Grant/Funding Number: DOD)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe